MX2013013384A - Metodo para tratamiento de cancer de pulmon de celulas no pequeñas. - Google Patents
Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.Info
- Publication number
- MX2013013384A MX2013013384A MX2013013384A MX2013013384A MX2013013384A MX 2013013384 A MX2013013384 A MX 2013013384A MX 2013013384 A MX2013013384 A MX 2013013384A MX 2013013384 A MX2013013384 A MX 2013013384A MX 2013013384 A MX2013013384 A MX 2013013384A
- Authority
- MX
- Mexico
- Prior art keywords
- lung cancer
- small cell
- cell lung
- nucleotides
- human patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical class CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un método de tratamiento de un paciente humano que padece de cáncer de pulmón que comprende administrar periódicamente al paciente humano quimioterapia que consiste en una cantidad de taxano y 640 mg de un oligonucleótido anti-clusterina que tiene la secuencia CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), en donde el oligonucleótido anti-clusterina tiene una columna de fosforotioato a lo largo, tiene porciones de azúcar de los nucleótidos 1-4 y 18-21 que llevan modificaciones de 2´-O-metoxietilo, tiene nucleótidos 5-17 los cuales son 2'desoxinucleótidos, y tiene 5-metilcitosinas en los nucleótidos 1, 4, y 19, con lo cual se trata al paciente humano que padece de cáncer de pulmón de células no pequeñas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487918P | 2011-05-19 | 2011-05-19 | |
| US201161493346P | 2011-06-03 | 2011-06-03 | |
| PCT/IB2012/001085 WO2012156817A2 (en) | 2011-05-19 | 2012-05-18 | Method for treating non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013013384A true MX2013013384A (es) | 2014-06-11 |
Family
ID=47177396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013384A MX2013013384A (es) | 2011-05-19 | 2012-05-18 | Metodo para tratamiento de cancer de pulmon de celulas no pequeñas. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20130017272A1 (es) |
| EP (1) | EP2709673A4 (es) |
| JP (1) | JP2014520081A (es) |
| KR (1) | KR20140034838A (es) |
| CN (1) | CN103958681A (es) |
| AR (1) | AR086514A1 (es) |
| AU (1) | AU2012257487A1 (es) |
| CA (1) | CA2836676A1 (es) |
| CL (1) | CL2013003324A1 (es) |
| EA (1) | EA201391725A1 (es) |
| IL (1) | IL227720A0 (es) |
| MX (1) | MX2013013384A (es) |
| PE (1) | PE20140647A1 (es) |
| PH (1) | PH12013502402A1 (es) |
| SG (1) | SG194931A1 (es) |
| WO (1) | WO2012156817A2 (es) |
| ZA (1) | ZA201309254B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144975A0 (en) | 1999-02-26 | 2002-06-30 | Univ British Columbia | A composition containing an antisense oligonucleotide |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| AU2012228010B2 (en) | 2011-03-15 | 2016-08-25 | The University Of British Columbia | Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer |
| UY34812A (es) * | 2012-05-18 | 2013-12-31 | Teva Pharma | Método para el tratamiento del cáncer de pulmón de células no pequeñas |
| US20140275215A1 (en) * | 2013-03-14 | 2014-09-18 | Teva Pharmaceutical Industries, Ltd. | Anti-clusterin monotherapy for cancer treatment |
| US20140275214A1 (en) * | 2013-03-14 | 2014-09-18 | Teva Pharmaceutical Industries, Ltd. | Custirsen treatment with reduced toxicity |
| US20160324439A1 (en) * | 2015-05-06 | 2016-11-10 | Taiwan Textile Research Institute | Stereoscopic conductive fabric and module for detecting electrical signals from body skin applying the same |
| WO2016191751A1 (en) * | 2015-05-28 | 2016-12-01 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| ES2987696T3 (es) * | 2015-05-29 | 2024-11-15 | Dynavax Tech Corp | Agonista polinucleotídico del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón |
| KR20190115505A (ko) | 2018-03-15 | 2019-10-14 | 특허법인 해담 | 기업 맞춤형 후속 개발 아이템 발굴 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| KR101265180B1 (ko) * | 2002-01-17 | 2013-05-29 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드, 이를 이용하여 약학적 조성물을 제조하는 방법 및 그 약학적 조성물 |
| US8710020B2 (en) * | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| EP1789460B1 (en) * | 2004-09-02 | 2013-01-09 | Isis Pharmaceuticals, Inc. | Polymeric beads for oligonucleotide synthesis |
-
2012
- 2012-05-18 WO PCT/IB2012/001085 patent/WO2012156817A2/en not_active Ceased
- 2012-05-18 PH PH1/2013/502402A patent/PH12013502402A1/en unknown
- 2012-05-18 CA CA2836676A patent/CA2836676A1/en not_active Abandoned
- 2012-05-18 JP JP2014510898A patent/JP2014520081A/ja active Pending
- 2012-05-18 MX MX2013013384A patent/MX2013013384A/es not_active Application Discontinuation
- 2012-05-18 US US13/475,780 patent/US20130017272A1/en not_active Abandoned
- 2012-05-18 KR KR1020137033743A patent/KR20140034838A/ko not_active Withdrawn
- 2012-05-18 EA EA201391725A patent/EA201391725A1/ru unknown
- 2012-05-18 SG SG2013083951A patent/SG194931A1/en unknown
- 2012-05-18 EP EP12786050.0A patent/EP2709673A4/en not_active Withdrawn
- 2012-05-18 CN CN201280030054.1A patent/CN103958681A/zh active Pending
- 2012-05-18 AU AU2012257487A patent/AU2012257487A1/en not_active Abandoned
- 2012-05-18 PE PE2013002522A patent/PE20140647A1/es not_active Application Discontinuation
- 2012-05-21 AR ARP120101802A patent/AR086514A1/es not_active Application Discontinuation
-
2013
- 2013-09-16 IL IL227720A patent/IL227720A0/en unknown
- 2013-11-19 CL CL2013003324A patent/CL2013003324A1/es unknown
- 2013-12-09 ZA ZA2013/09254A patent/ZA201309254B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12013502402A1 (en) | 2014-01-13 |
| KR20140034838A (ko) | 2014-03-20 |
| EP2709673A2 (en) | 2014-03-26 |
| IL227720A0 (en) | 2013-09-30 |
| CL2013003324A1 (es) | 2014-08-01 |
| AR086514A1 (es) | 2013-12-18 |
| CA2836676A1 (en) | 2012-11-22 |
| ZA201309254B (en) | 2015-05-27 |
| US20130017272A1 (en) | 2013-01-17 |
| SG194931A1 (en) | 2013-12-30 |
| CN103958681A (zh) | 2014-07-30 |
| AU2012257487A1 (en) | 2014-01-16 |
| WO2012156817A3 (en) | 2013-02-21 |
| EP2709673A4 (en) | 2014-12-17 |
| PE20140647A1 (es) | 2014-06-05 |
| JP2014520081A (ja) | 2014-08-21 |
| WO2012156817A9 (en) | 2013-01-03 |
| WO2012156817A2 (en) | 2012-11-22 |
| EA201391725A1 (ru) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013013384A (es) | Metodo para tratamiento de cancer de pulmon de celulas no pequeñas. | |
| EA201492148A1 (ru) | Способ лечения немелкоклеточного рака легких | |
| MX359548B (es) | Agentes de iarn modificados. | |
| Krützfeldt | Strategies to use microRNAs as therapeutic targets | |
| CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
| PH12015501953A1 (en) | Substituted nucleotide analogs | |
| RU2019130513A (ru) | Антисмысловые нуклеиновые кислоты | |
| WO2011038160A3 (en) | Compositions and methods for silencing genes expressed in cancer | |
| MX354940B (es) | Oligonucleotidos funcionalmente modificados y subunidades de los mismos. | |
| SG171676A1 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
| US20140356459A1 (en) | Micrornas and uses thereof | |
| WO2009017803A3 (en) | Antisense microrna and uses therefor | |
| Wang et al. | The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells | |
| Liu et al. | miR-22 functions as a micro-oncogene in transformed human bronchial epithelial cells induced by anti-benzo [a] pyrene-7, 8-diol-9, 10-epoxide | |
| EP2604690A1 (en) | MicroRNAs and uses thereof | |
| IN2014CN03921A (es) | ||
| AR091327A1 (es) | DISEÑO DE ARNhc BIFUNCIONAL EN EL SARCOMA DE EWING | |
| MX348555B (es) | Agente preventivo o terapeutico contra la fibrosis. | |
| Tan et al. | Potential microRNA targets for cancer chemotherapy | |
| AR095416A1 (es) | Tratamiento con cutirsen que presenta una toxicidad reducida | |
| WO2012058462A3 (en) | Combination therapy for the treatment of cancer | |
| WO2011087343A3 (ko) | Ｈｐｖ 감염과 관련된 암의 치료용 조성물 | |
| KR101206374B1 (ko) | 이중가닥 마이크로 ｒｎａ를 유효성분으로 포함하는 항암제 | |
| WO2012131673A3 (en) | Ccat-1 silencing nucleic acid agents for treating cancer | |
| AR095559A1 (es) | Monoterapia con oligonucleótidos anti-clusterina para tratar el cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |